https://www.fortunebusinessinsights.com/artificial-intelligence-in-drug-discovery-market-105354

Artificial Intelligence (AI) in Drug Discovery Market
Rising Use in Virtual Screening | 2030 Forecast
The AI in drug discovery market refers to the use of artificial intelligence—especially machine learning,
deep learning, and generative modeling—to speed up and enhance early-stage drug development. These
technologies facilitate tasks like identifying new targets, designing molecules, optimizing drug candidates,
and predicting clinical trial outcomes. AI-driven approaches significantly reduce the time and cost compared
to traditional methods, helping address the extensive timelines and high failure rates typical in pharma R&D.
The market is growing swiftly thanks to rising R&D investments, access to vast biomedical datasets, and
strategic partnerships between pharma companies and AI startups. North America leads the market, with
Asia-Pacific emerging rapidly due to expanding healthcare infrastructure and increasing digitization of
research.
According to Fortune Business Insights, the global artificial intelligence (AI) in drug discovery market was
valued at USD 3.00 billion in 2022 and is projected to grow from USD 3.54 billion in 2023 to USD 7.94
billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.2% during the forecast period
(2023–2030). In 2022, North America dominated the market with a 69.33% share.